January 20, 2022      Patent filed

 

“Combination cancer therapy with DYRK1 inhibitors and inhibitors of the RAS-RAF-MEK-ERK (MAPK) pathway”, unpublished, filed January 20, 2022

Patent granted

 

"Combinations for the treatment of cancer using quiescent cell targeting and inhibitors of mitosis"

Patent granted

 

“Combinations for the treatment of neoplasms using quiescent cell targeting with EGFR inhibitors” 

March 2022          

 

"A Cell Double-Barcoding System for Quantitative Evaluation of Primary Tumors and Metastasis in Animals That Uncovers Clonal-Specific Anti-Cancer Drug Effects"

January 2021           

 

"DYRK1A regulates B cell acute lymphoblastic leukemia through phosphorylation of FOXO1 and STAT3"

April 28, 2020        AACR Annual Meeting

 

Abstract Number: 5161

Validation of drug candidates targeting dormant cancers in live cells as a key for successful translation into the clinics

March, 2020           Patent granted

May 26, 2019         ASCO Annual Meeting Presentation

 

Abstract Number: 14670

Implication of DYRK1B kinase in dormant glioblastoma cancers and utilization of DYRK1B inhibitors as a novel therapeutic strategy for glioblastoma.

April 2, 2019          AACR Annual Meeting Presentation

 

Abstract Number: 3038

Implications of DYRK1B kinase in ovarian cancers and utilization of DYRK1B inhibitors as a novel therapeutic strategy for ovarian cancers

February, 2019      Journal of Molecular Modeling

January 11, 2016      8th Annual BIOTECH Showcase

Oral presentation

Date and Time:  January 13th 2016 8AM

Location: The Parc 55 San Francisco Track A

 © 2019 by Felicitex Therapeutics, Inc »«                                                        

Felicitex Therapeutics Inc.

27 Strathmore Rd.

Natick, MA 01760

(919) 213-0025